Tremfya™ (guselkumab) is a biologic approved for the treatment moderate-to-severe plaque psoriasis in...
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.
Getting Acquainted with the Theory of XRF
This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.
Mitochondrial Testing Services
Mitochondria are present in every cell of the body. They maintain cell homeostasis by controlling energy production, ion fluxes and the rate-limiting step of steroidogenesis.
May’s top news stories
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.
NIH supports genomic medicine trials for chronic diseases
The US National Institute of Health (NIH) has agreed to fund clinical trials investigating the practicality and effectiveness of using genomics data as part of treatments for chronic disease such as high blood pressure, depression and chronic pain.
Detecting the Presence of Trace Polymorphs and Impurities
In the pharmaceutical industry, the detection of polymorph traces is one of the most important applications of powder x-ray diffraction (PXRD).
Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Olumiant® (baricitinib) is one of the first once-daily oral selective JAK1 and JAK2 inhibitors for the treatment of moderate-to-severe active rheumatoid arthritis (RA).
Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma
Cabometyx (cabozantinib) is used for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.